Inclusion Criteria:

Disease Characteristics

- The patient must be 18 years of age or older.

- The patient must have squamous cell carcinoma of the head and neck.

- The squamous cell carcinoma must be Ep-CAM positive.

- ECOG performance status of 0, 1, 2 or 3.

- 12 week life expectancy

Prior/Concurrent Therapy

- The patient must have received therapy for their primary disease (eg, surgery and/or
radiotherapy, chemo-radiotherapy or chemotherapy).

- The patient must have been diagnosed with persistent or recurrent disease or a second
primary tumour.

- The patient's disease must be refractory.

- There must be at least 2 weeks between the last dose of chemotherapy or radiotherapy
and receiving study drug or 4 weeks between the last dose of an experimental drug and
receiving study drug.

Patient Characteristics

- The patient must have adequate hepatic function [alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) ≤2.5 × upper limit of normal (ULN) and bilirubin
level ≤1.5 × ULN].

- The patient must have adequate renal function (serum creatinine < 1.5 × ULN).

- The patient must have the following hematological values: granulocytes ≥1500/μL,
platelets ≥75 000/μL and hemoglobin >8 g/dL.

- The patient must have prothrombin time and partial thromboplastin time within normal
limits.

Other

• Women of childbearing potential and male patients must agree to use a highly effective
contraceptive method.

Exclusion Criteria:

- The patient has clinically significant distant metastases.

- The patient is eligible to have surgical resection or radiotherapy,
chemo-radiotherapy or chemotherapy.

- The patient has a nasopharyngeal tumour.

- The patient has AIDS, hepatitis C or hepatitis B.

- The patient has clinically significant renal or hepatic disease.

- Tumors are prone to bleeding.

- The patient is pregnant or lactating.

- The patient requires 'blood thinning' medications and can not safely discontinue the
medication.

- The patient is currently enrolled in another clinical trial.